Loading...

Fennec Pharmaceuticals

DB:RV41
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RV41
DB
$94M
Market Cap
Add to portfolio
  1. Home
    2. ›
  2. DE
    3. ›
  3. Pharmaceuticals & Biotech
Last updated 2019/04/18 20:38
Company description

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. The last earnings update was 34 days ago. More info.

Find similar companies

Add to Portfolio Compare Print
  • Fennec Pharmaceuticals has significant price volatility in the past 3 months.
RV41 Share Price and Events
7 Day Returns
-3.1%
DB:RV41
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-62.3%
DB:RV41
-9.2%
DE Biotechs
-6.7%
DE Market
RV41 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Fennec Pharmaceuticals (RV41) -3.1% -16.1% -33.8% -62.3% 119.9% 164.9%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • RV41 underperformed the Biotechs industry which returned -9.2% over the past year.
  • RV41 underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
RV41
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Fennec Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Fennec Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €4.069.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Fennec Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Fennec Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:RV41 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.52
NasdaqCM:FENC Share Price ** NasdaqCM (2019-04-18) in USD $4.72
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Fennec Pharmaceuticals.

DB:RV41 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:FENC Share Price ÷ EPS (both in USD)

= 4.72 ÷ -0.52

 -9.04x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fennec Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Fennec Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Fennec Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:RV41 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.04x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts		 42.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Fennec Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Fennec Pharmaceuticals's assets?
Raw Data
DB:RV41 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.07
NasdaqCM:FENC Share Price * NasdaqCM (2019-04-18) in USD $4.72
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:RV41 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:FENC Share Price ÷ Book Value per Share (both in USD)

= 4.72 ÷ 1.07

 4.41x

* Primary Listing of Fennec Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Fennec Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Fennec Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
    5. Fennec Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Fennec Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
42.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Fennec Pharmaceuticals expected to grow at an attractive rate?
  • Fennec Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Fennec Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Fennec Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:RV41 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:RV41 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 42.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:RV41 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:RV41 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 131 62 2
2022-12-31 91 37 2
2021-12-31 44 9 2
2020-12-31 20 64 2
2019-12-31 0 -13 3
DB:RV41 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -8 -10
2018-09-30 -6 -9
2018-06-30 -6 -9
2018-03-31 -5 -8
2017-12-31 -4 -7
2017-09-30 -3 -6
2017-06-30 -3 -4
2017-03-31 -2 -3
2016-12-31 -2 -3
2016-09-30 -2 -2
2016-06-30 -2 -2
2016-03-31 -2 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Fennec Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Fennec Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:RV41 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Fennec Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RV41 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.76 2.99 2.53 2.00
2022-12-31 1.62 2.08 1.15 2.00
2021-12-31 0.39 0.44 0.33 2.00
2020-12-31 3.14 3.14 3.14 1.00
2019-12-31 -0.62 -0.46 -0.83 3.00
DB:RV41 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.52
2018-09-30 -0.51
2018-06-30 -0.51
2018-03-31 -0.48
2017-12-31 -0.47
2017-09-30 -0.41
2017-06-30 -0.29
2017-03-31 -0.24
2016-12-31 -0.22
2016-09-30 -0.18
2016-06-30 -0.16
2016-03-31 -0.12

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Fennec Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Show me more growth companies in the Biotechs industry
X
Future performance checks
We assess Fennec Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Fennec Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Fennec Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Fennec Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Fennec Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Fennec Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Fennec Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Fennec Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Fennec Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RV41 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -9.89 5.40 5.01
2018-09-30 -9.19 5.65 4.17
2018-06-30 -8.80 6.29 2.87
2018-03-31 -7.81 5.57 2.40
2017-12-31 -7.05 5.02 1.94
2017-09-30 -5.90 4.36 1.22
2017-06-30 -4.05 3.12 0.84
2017-03-31 -3.18 2.54 0.65
2016-12-31 -2.79 2.40 0.47
2016-09-30 -2.19 1.91 0.37
2016-06-30 -1.81 1.71 0.35
2016-03-31 -1.26 1.63 0.26
2015-12-31 -0.66 1.63 0.26
2015-09-30 1.27 1.78 0.35
2015-06-30 1.77 2.06 0.35
2015-03-31 1.20 2.42 0.37
2014-12-31 -2.18 2.52 0.36
2014-09-30 -2.45 2.22 0.28
2014-06-30 -4.60 1.97 -0.03
2014-03-31 2.76 1.48 0.45
2013-12-31 1.85 1.33 0.60
2013-09-30 -5.78 1.57 1.07
2013-06-30 -4.78 1.57 1.65
2013-03-31 -11.99 1.58 1.96
2012-12-31 -5.16 1.55 2.08
2012-09-30 4.86 1.38 2.02
2012-06-30 2.48 1.61 2.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Fennec Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Fennec Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Fennec Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Fennec Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Fennec Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Fennec Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Fennec Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Fennec Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Fennec Pharmaceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Fennec Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Fennec Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Fennec Pharmaceuticals Company Filings, last reported 3 months ago.

DB:RV41 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 21.31 0.00 22.78
2018-09-30 22.86 0.00 24.52
2018-06-30 24.86 0.00 25.64
2018-03-31 25.66 0.00 26.72
2017-12-31 26.76 0.00 28.26
2017-09-30 8.86 0.00 9.69
2017-06-30 9.68 0.00 10.23
2017-03-31 2.86 0.00 3.25
2016-12-31 3.57 0.00 3.93
2016-09-30 4.22 0.00 4.54
2016-06-30 4.65 0.00 5.08
2016-03-31 0.24 0.00 0.55
2015-12-31 0.55 0.00 0.94
2015-09-30 1.02 0.00 1.37
2015-06-30 1.11 0.00 1.85
2015-03-31 0.83 0.00 1.92
2014-12-31 0.61 0.00 2.31
2014-09-30 -3.23 0.00 0.59
2014-06-30 -4.66 0.00 1.02
2014-03-31 -4.33 0.00 1.34
2013-12-31 -1.46 0.00 1.66
2013-09-30 -4.13 0.00 0.54
2013-06-30 -2.43 0.00 1.01
2013-03-31 -9.07 0.00 1.90
2012-12-31 -4.96 0.00 2.30
2012-09-30 1.28 0.00 2.86
2012-06-30 2.05 0.00 3.59
  • Fennec Pharmaceuticals has no debt.
  • Fennec Pharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Fennec Pharmaceuticals has sufficient cash runway for 2.9 years based on current free cash flow.
  • Fennec Pharmaceuticals has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 52.7% each year.
Show me more healthy companies in the Biotechs industry
X
Financial health checks
We assess Fennec Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
    7. Fennec Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Fennec Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Fennec Pharmaceuticals dividends.
If you bought €2,000 of Fennec Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Fennec Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Fennec Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:RV41 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:RV41 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Fennec Pharmaceuticals has not reported any payouts.
  • Unable to verify if Fennec Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Fennec Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Fennec Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Fennec Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Fennec Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
    7. Fennec Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Fennec Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rosty Raykov
COMPENSATION $1,072,261
AGE 42
TENURE AS CEO 9.8 years
CEO Bio

Mr. Rostislav Raykov, also known as Rosty, has been the Chief Executive Officer of Fennec Pharmaceuticals Inc. (alternate name Adherex Technologies Inc) since July 2009 and serves as its President. Mr. Raykov is a General Partner at DCML, a private investment partnership. Mr. Raykov has financial expertise and experience with Fennec. He served as a General Partner of Alchem Investment Partners from January 2006 to December 2007, an event driven hedge fund. He was a Portfolio Manager Alchem Partners. Mr. Raykov was a Portfolio Manager and Securities Analyst for John A. Levin & Co. Event Driven Fund from 2002 to 2005. Mr. Raykov was a Securities Analyst for the Merger Fund at Tiedemann Investment Group from 1999 to 2002 and an Investment Banking Analyst at Bear Stearns from 1998 to 1999. He served as Chairman of Fennec Pharmaceuticals Inc. from August 2013 to December 9, 2015 and has been its Director since July 2009. He served as an Independent Director at Wesdome Gold Mines Ltd. since August 26, 2013. Mr. Raykov has been an Independent Director at Amarillo Gold Corp. since July 19, 2013. Mr. Raykov earned a BS in Business Administration from the University of North Carolina at Chapel Hill.

CEO Compensation
  • Rosty's compensation has increased whilst company is loss making.
  • Rosty's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Fennec Pharmaceuticals management team in years:

6.2
Average Tenure
43
Average Age
  • The average tenure for the Fennec Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Rosty Raykov

TITLE
CEO & Director
COMPENSATION
$1M
AGE
42
TENURE
9.8 yrs

Robert Andrade

TITLE
Chief Financial Officer
COMPENSATION
$669K
AGE
43
TENURE
3.4 yrs

Mark Gowland

TITLE
Controller
TENURE
3.4 yrs

Lei Fang

TITLE
President of Pharstat Inc

Anne McKay

TITLE
Regulatory Consultant
AGE
64
TENURE
8.9 yrs

Lex Smith

TITLE
Consultant
Board of Directors Tenure

Average tenure and age of the Fennec Pharmaceuticals board of directors in years:

5
Average Tenure
63
Average Age
  • The tenure for the Fennec Pharmaceuticals board of directors is about average.
Board of Directors

Khalid Islam

TITLE
Chairman of the Board
COMPENSATION
$353K
AGE
63
TENURE
3.3 yrs

Rosty Raykov

TITLE
CEO & Director
COMPENSATION
$1M
AGE
42
TENURE
9.8 yrs

Chris Rallis

TITLE
Independent Director
COMPENSATION
$260K
AGE
64
TENURE
7.7 yrs

Adrian Haigh

TITLE
Independent Director
COMPENSATION
$257K
AGE
59
TENURE
5 yrs

Marco Brughera

TITLE
Independent Director
COMPENSATION
$257K
AGE
63
TENURE
2.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
10. Sep 18 Sell Manchester Management Company, LLC Company 20. Aug 18 06. Sep 18 -279,113 €8.55 €-2,303,436
27. Jun 18 Sell Morgan Frank Individual 08. Jun 18 08. Jun 18 -3,000 €9.17 €-27,524
27. Jun 18 Sell Manchester Management Company, LLC Company 07. May 18 27. Jun 18 -325,533 €10.51 €0
18. May 18 Sell James Besser Individual 20. Apr 18 03. May 18 -83,333 €11.22 €-935,370
X
Management checks
We assess Fennec Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
    5. Fennec Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Details
Name: Fennec Pharmaceuticals Inc.
RV41
Exchange: DB
Founded: 1996
$83,540,839
19,895,830
Website: http://www.fennecpharma.com
Address: Fennec Pharmaceuticals Inc.
68 TW Alexander Drive,
PO Box 13628,
Research Triangle Park,
North Carolina, 27709,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM FENC Common Shares Nasdaq Capital Market US USD 05. Jun 2001
DB RV41 Common Shares Deutsche Boerse AG DE EUR 05. Jun 2001
TSX FRX Common Shares The Toronto Stock Exchange CA CAD 05. Jun 2001
BST RV41 COM NPV Boerse-Stuttgart DE EUR 18. Apr 2019
Number of employees
Current staff
Staff numbers
3
Fennec Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 20:38
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/14
Last earnings filing: 2019/03/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Related Companies

© 2019 Simply Wall Street Pty Ltd, Community Design 2845206, US Design Patent #29/544/281, European Design Registration #2845206, Standard & Poor’s Financial Services LLC. All rights reserved.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2019, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2019)